PRKCE and prostate carcinoma: These authors further showed that treatment of prostate cancer cells with MK591, a 5-LOX inhibitor, or 5-LOX shRNA not only decreased PKCε expression but also diminished membrane localization of PKCε, inducing apoptosis.